Federal Register of Legislation - Australian Government

Primary content

Determinations/Health as made
This instrument amends the Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018 to enable testing provided under item 73343 for patients with relapsed or refractory chronic lymphoid leukaemia or small lymphocytic lymphoma, to determine eligibility for venetoclax, in addition to ibrutinib and idelalisib, under the Pharmaceutical Benefits Scheme.
Administered by: Health
Registered 22 Feb 2019
Tabling HistoryDate
Tabled HR02-Apr-2019
Tabled Senate02-Apr-2019
Date of repeal 12 Sep 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003
Enabled by
Authoritative version Health Insurance Act 1973
C2004A00101No. 42, 1974